Numerous studies have shown that in clinical applications, SCD1 inhibitors (thiazol-4-acetic acid derivatives) have therapeutic potential for obesity, cancer and diabetes, but it may produce associated clinical adverse reactions (Iida et al., 2018). This evidence concerns the gene SCD and obesity disorder.